fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-02-08
Biotech partner: Johns Hopkins University (USA) Qiagen (The Netherlands)
Type of agreement: * licensing
Compound: biomarker PI3K
Disease area: cancer
Nature of the agreement: Qiagen's wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies suggest that mutations in the PI3K oncogene are predictive for the success of certain treatments of patients suffering from lung, breast, colorectal and other cancers.
Qiagen has an active PI3K assay development and partnering program with pharmaceutical companies to develop and market tests for new cancer drug candidates. The company already markets a PI3K test for research use. This test is based on real-time polymerase chain reaction (RT-PCR).

Financial terms of the agreement: Financial details were not disclosed.


Go back to previous page